Testing three medicines for previously treated soft-tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have soft-tissue sarcoma that has spread or cannot be removed surgically
- You have already received anti-cancer treatment for your sarcoma
- You can have measurable tumors seen on scans, and your last scan shows “measurable disease”
- You are well enough to do daily activities (ECOG 0 or 1) and are expected to live at least 3 months
- Your blood, kidney, and liver tests are within the trial’s limits
- You can sign consent and will be able to follow all study visits and treatment plans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
This Phase 3 trial tests trabectedin (in tTF-NGR study) for people with advanced or metastatic soft-tissue sarcoma whose first treatment with anthracycline drugs didn’t work (or can’t be used). It aims to see if this approach works better than the study comparison treatment, using tumor response and other safety outcomes.
This trial tests a combination of three drugs—liposomal irinotecan, temozolomide, and bevacizumab—for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery and has not responded to previous treatments. The goal is to see if this combination can help control the cancer.
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
Hear when a new Advanced Soft-tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.